Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax After TKI to Target Persisting Stem Cells in CML

NCT05701215 is registered in ClinicalTrials.gov with Thomas Ernst, PD Dr. med. as lead sponsor.

NCT NCT05701215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05701215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax After TKI to Target Persisting Stem Cells in CML
Lead sponsor
Thomas Ernst, PD Dr. med.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2023
Completion date
May 31, 2026
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia